Logo

VTYX

Ventyx Biosciences, Inc.

VTYX

Ventyx Biosciences, Inc. • NASDAQ
$9.99 ▲ 0.05% (+0.01)
Market Cap $713.23 M
52w High $10.55
52w Low $0.78
Dividend Yield 0%
P/E -6.71
Volume 382.11K
Outstanding Shares 71.36M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $24.874M ▼ $-22.829M ▲ 0% $-0.32 ▲ $-22.768M ▲
Q2-2025 $0 $29.333M ▼ $-26.987M ▲ 0% $-0.38 ▲ $-29.01M ▲
Q1-2025 $0 $30.097M ▼ $-27.44M ▲ 0% $-0.39 ▲ $-29.741M ▲
Q4-2024 $0 $32.418M ▼ $-29.351M ▲ 0% $-0.41 ▲ $-32.103M ▲
Q3-2024 $0 $38.552M $-35.249M 0% $-0.5 $-38.243M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $192.638M ▼ $211.465M ▼ $20.101M ▼ $191.364M ▼
Q2-2025 $208.959M ▼ $230.009M ▼ $20.626M ▼ $209.383M ▼
Q1-2025 $228.807M ▲ $253.48M ▼ $21.847M ▼ $231.633M ▼
Q4-2024 $217.322M ▼ $276.563M ▼ $22.518M ▲ $254.045M ▼
Q3-2024 $274.825M $301.1M $22.328M $278.772M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-22.829M ▲ $-17.508M ▲ $17.051M ▼ $203K ▲ $-331K ▼ $-17.558M ▲
Q2-2025 $-26.987M ▲ $-21.277M ▲ $25.192M ▼ $68K ▲ $4.225M ▲ $-21.319M ▲
Q1-2025 $-27.44M ▲ $-25.718M ▼ $26.415M ▲ $0 ▲ $816K ▲ $-25.734M ▼
Q4-2024 $-29.351M ▲ $-23.249M ▲ $-10.998M ▼ $-25K ▼ $-34.505M ▼ $-23.255M ▲
Q3-2024 $-35.249M $-35.461M $29.247M $26.862M $20.84M $-35.461M

Five-Year Company Overview

Income Statement

Income Statement Ventyx is still a pure R&D story with no product revenue yet. Its entire income statement is driven by research and development and corporate expenses, which translate into consistent operating and net losses each year. Losses have grown as the pipeline has expanded and trials have moved forward, with a slight easing most recently but still meaningfully in the red. This pattern is typical for a clinical‑stage biotech that is investing heavily ahead of any commercial launch, but it also means the company is entirely dependent on external funding until meaningful revenue appears.

Balance Sheet

Balance Sheet The balance sheet shows a company funded mainly by equity with very little debt, which reduces financial strain from interest payments. Total assets and cash have come down from earlier levels, reflecting ongoing cash use to fund clinical work. Shareholders’ equity remains solidly positive, suggesting prior financings have built a reasonable capital base, but the gradual erosion of cash and assets underlines that the company’s financial strength is closely tied to its ability to raise new capital over time or secure partnerships.

Cash Flow

Cash Flow Cash flow is consistently negative, driven by operating cash outflows tied to R&D and overhead, with essentially no spending on property or equipment. Free cash flow therefore mirrors the operating burn. The trend shows increasing cash use as the pipeline advanced, with a modest improvement more recently but still a meaningful ongoing burn rate. This reinforces that Ventyx will likely need periodic access to capital markets or partnership funding to sustain its current pace of development.

Competitive Edge

Competitive Edge Ventyx operates in highly competitive immunology and inflammation markets, going up against large pharmaceutical companies and other biotech innovators. Its strategy focuses on convenient oral small molecules targeting well‑validated pathways where many existing treatments are injectable biologics. That convenience angle, combined with attempts at better safety or tolerability, could be an advantage if the data ultimately support it. However, being clinical‑stage with no approved products means it currently lacks commercial scale, real‑world prescribing experience, and the marketing muscle of larger rivals, so its competitive position will hinge heavily on the strength of upcoming clinical results and any strategic partnerships it can secure.

Innovation and R&D

Innovation and R&D The company is clearly R&D‑driven, with a pipeline centered on NLRP3 inhibitors and an S1P1 modulator for autoimmune and inflammatory diseases. It is targeting biologically validated pathways, aiming for more selective, oral options that could match or improve upon existing therapies in efficacy, safety, or ease of use. The discontinuation of its TYK2 program shows active portfolio management and a willingness to cut assets that may not be competitive, which can be a positive discipline but also highlights the inherent risk of drug development. Future innovation will likely come from advancing current candidates through late‑stage trials, expanding into new indications like cardiovascular disease, and progressing earlier discovery programs, potentially supported by collaborations with larger pharma companies.

Summary

Overall, Ventyx looks like a classic early‑stage biotech: no revenue, steady and meaningful losses, and a balance sheet funded mainly by past equity raises. Its value is concentrated in its scientific platform and pipeline rather than in current financial performance. The company’s focus on oral, small‑molecule therapies for inflammatory and autoimmune diseases, including differentiated NLRP3 inhibitors and an S1P1 modulator, provides clear scientific and strategic direction. At the same time, the lack of commercial products, the ongoing cash burn, and the competitive nature of its target markets mean outcomes depend heavily on future clinical data, regulatory progress, and access to funding or partners. Investors and stakeholders will likely focus most on trial readouts, cash runway, and the company’s ability to convert its R&D investments into approvable, commercially viable drugs over the coming years.

NEWS

November 17, 2025 · 7:02 AM UTC

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Read more

November 6, 2025 · 4:02 PM UTC

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Read more

October 22, 2025 · 4:02 PM UTC

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Read more